1
项与 γ-globin gene therapy(CSL Behring LLC) 相关的临床试验A Phase 1 Pilot Study to Evaluate the Safety and Feasibility of Gene Therapy With CSL200 (Autologous Enriched CD34+ Cell Fraction That Contains CD34+ Cells Transduced With Lentiviral Vector Encoding Human γ-GlobinG16D and Short-Hairpin RNA734) in Adult Subjects With Severe Sickle Cell Disease
This is a phase 1 pilot study of CSL200 in adult subjects with severe sickle cell disease. The primary objectives of this study are to evaluate the safety of the following: collection of CD34+ hematopoietic stem / progenitor cells by apheresis after mobilization with plerixafor, reduced intensity conditioning with melphalan, and administration of CSL200.
100 项与 γ-globin gene therapy(CSL Behring LLC) 相关的临床结果
100 项与 γ-globin gene therapy(CSL Behring LLC) 相关的转化医学
100 项与 γ-globin gene therapy(CSL Behring LLC) 相关的专利(医药)
100 项与 γ-globin gene therapy(CSL Behring LLC) 相关的药物交易